120 related articles for article (PubMed ID: 21615212)
1. From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.
Zhang S; Farag SS
Expert Opin Investig Drugs; 2011 Jul; 20(7):1015-28. PubMed ID: 21615212
[TBL] [Abstract][Full Text] [Related]
2. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract][Full Text] [Related]
3. ENMD-2076 for hematological malignancies.
How J; Yee K
Expert Opin Investig Drugs; 2012 May; 21(5):717-32. PubMed ID: 22397360
[TBL] [Abstract][Full Text] [Related]
4. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
Altenburg JD; Farag SS
Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
[TBL] [Abstract][Full Text] [Related]
5. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
6. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
Matulonis UA; Lee J; Lasonde B; Tew WP; Yehwalashet A; Matei D; Behbakht K; Grothusen J; Fleming G; Lee NK; Arnott J; Bray MR; Fletcher G; Brokx RD; Castonguay V; Mackay H; Sidor CF; Oza AM
Eur J Cancer; 2013 Jan; 49(1):121-31. PubMed ID: 22921155
[TBL] [Abstract][Full Text] [Related]
7. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
8. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
Moreau P
Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
10. Emerging pathways as individualized therapeutic target of multiple myeloma.
Misso G; Zappavigna S; Castellano M; De Rosa G; Di Martino MT; Tagliaferri P; Tassone P; Caraglia M
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S95-109. PubMed ID: 23738692
[TBL] [Abstract][Full Text] [Related]
11. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
Yap TA; Olmos D; Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
[TBL] [Abstract][Full Text] [Related]
13. Preclinical models of multiple myeloma: a critical appraisal.
Schüler J; Ewerth D; Waldschmidt J; Wäsch R; Engelhardt M
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S111-23. PubMed ID: 23742200
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
15. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
18. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Vallet S; Witzens-Harig M; Jaeger D; Podar K
Expert Opin Pharmacother; 2012 Mar; 13(4):473-94. PubMed ID: 22324734
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide therapy for myeloma.
Schey S; Ramasamy K
Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
[TBL] [Abstract][Full Text] [Related]
20. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
